It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency (EMA). Nevertheless, the director of Alzheimer Nederland, Gerjoke Wilmink, is pleased with the approval of the drug, even though it has a modest effect."In twenty years' time, we will remember this day as a very important first step in the treatment of dementia. I am convinced of that," says Wilmink.